Global leader in AI and robotics drug-discovery
technologies selects AWS as its cloud provider
XtalPi uses generative AI to enable faster and
more cost-efficient research, data mining, and analysis
At AWS re:Invent, Amazon Web Services, Inc. (AWS), an
Amazon.com, Inc. company (NASDAQ: AMZN), today announced that
XtalPi, a leading global technology company that combines
artificial intelligence (AI) and robotics to drive the discovery of
medicine and innovative materials, has selected AWS as its
strategic cloud provider. XtalPi uses AI, quantum physics, and
robotics to drive innovation in life sciences, chemistry, and new
materials. Using AWS, XtalPi helps hundreds of companies, including
16 of the world’s top 20 pharmaceutical companies, expedite drug
discovery and development, ensure data security and privacy
compliance, and enhance their success rates in developing promising
new therapies for patients.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20241204853282/en/
(Graphic: Business Wire)
Using Amazon Bedrock to pinpoint promising areas for
drug research
XtalPi offers a suite of computational tools and platforms to
advance pharmaceutical and new-materials research. Combining
quantum physics, computational chemistry, and AI, XtalPi empowers
scientists to efficiently explore areas for the design and rapid
screening of molecules with desired properties and functions. Most
recently, XtalPi developed and launched PatSight, a patent
data-mining and analysis platform, in collaboration with
International Digital Economy Academy (IDEA). Using Amazon Bedrock,
PatSight analyzes thousands of compound structures and key
properties in an hour versus manual processes that can take several
weeks. Anthropic Claude 3 Opus provides contextual understanding
and textual range of 200,000 tokens (about 150,000 words or 500
pages of text), enabling PatSight to achieve more than 95% accuracy
in determining if a molecule or chemical compound is covered by
existing drug patents.
“AWS’s flexible, secure, and scalable approach to generative AI
makes it easy to create solutions that enhance drug development and
speed the delivery of successful treatment approaches,” said
Yongpan Chen, head of the Digitalization Department at XtalPi.
“With industry-leading security and compliance practices, AWS
empowers XtalPi to continuously enhance the capability of our
platforms as our business continues to expand. We look forward to
deepening our collaboration with AWS to apply cloud technologies
and power digital transformation in life sciences and materials
science on a broader scale.”
Rapidly delivering new features with Amazon Q
XtalPi's software developers use Amazon Q Developer, a
generative AI assistant for software development, to help its IT
teams quickly transform code, generate suggestions, optimize
performance, and conduct vulnerability scans, significantly
enhancing Java development and enabling greater focus on
application innovation. Additionally, Amazon Q Developer's
customization features help XtalPi developers to integrate it with
enterprise system data, creating a knowledge base of reusable code,
which leads to better code suggestions and faster application
deployment.
Enhancing efficiency and the success rate of drug discovery
with Amazon SageMaker
XtalPi uses Amazon Elastic Kubernetes Service (Amazon EKS), a
managed service to run Kubernetes, to simplify container deployment
and scaling while reducing costs and improving resource efficiency.
XtalPi also leverages Amazon EC2 Spot Instances, which offer
compute capacity at up to a 90% discount, to enhance research and
development efficiency and cut operational and maintenance costs by
more than 50%. By integrating Amazon SageMaker into its AI
drug-discovery platform, XtalPi can accelerate the creation and
deployment of machine learning models to help advance its AI and
robotics platform.
“AWS’s security and scalability allow XtalPi to develop
cloud-based platforms that enhance the efficiency of drug research
for leading pharmaceutical companies worldwide,” said Deepak Nair,
director, Healthcare and Life Sciences at AWS. “AI-driven workflows
are poised to transform the rate at which we can move through the
drug-discovery process, driving new therapy breakthroughs with
lower development costs and faster delivery of lifesaving
treatments.”
About Amazon Web Services
Since 2006, Amazon Web Services has been the world’s most
comprehensive and broadly adopted cloud. AWS has been continually
expanding its services to support virtually any workload, and it
now has more than 240 fully featured services for compute, storage,
databases, networking, analytics, machine learning and artificial
intelligence (AI), Internet of Things (IoT), mobile, security,
hybrid, media, and application development, deployment, and
management from 108 Availability Zones within 34 geographic
regions, with announced plans for 18 more Availability Zones and
six more AWS Regions in Mexico, New Zealand, the Kingdom of Saudi
Arabia, Taiwan, Thailand, and the AWS European Sovereign Cloud.
Millions of customers—including the fastest-growing startups,
largest enterprises, and leading government agencies—trust AWS to
power their infrastructure, become more agile, and lower costs. To
learn more about AWS, visit aws.amazon.com.
About Amazon
Amazon is guided by four principles: customer obsession rather
than competitor focus, passion for invention, commitment to
operational excellence, and long-term thinking. Amazon strives to
be Earth’s Most Customer-Centric Company, Earth’s Best Employer,
and Earth’s Safest Place to Work. Customer reviews, 1-Click
shopping, personalized recommendations, Prime, Fulfillment by
Amazon, AWS, Kindle Direct Publishing, Kindle, Career Choice, Fire
tablets, Fire TV, Amazon Echo, Alexa, Just Walk Out technology,
Amazon Studios, and The Climate Pledge are some of the things
pioneered by Amazon. For more information, visit amazon.com/about
and follow @AmazonNews.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241204853282/en/
Amazon.com, Inc. Media Hotline Amazon-pr@amazon.com
www.amazon.com/pr
Amazon.com (NASDAQ:AMZN)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
Amazon.com (NASDAQ:AMZN)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
